Entinostat - Syndax Pharmaceuticals

Drug Profile

Entinostat - Syndax Pharmaceuticals

Alternative Names: EDP-103; Entinostat; KHK-2375; MS-27-275; MS-275; SND 275; SNDX-275

Latest Information Update: 13 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nihon Schering; Pfizer; University of Tokyo
  • Developer Columbia University; Eddingpharm; Genentech; Indiana University; Kyowa Hakko Kirin; Memorial Sloan-Kettering Cancer Center; Merck & Co; National Cancer Institute (USA); Pfizer; Roswell Park Cancer Institute; Syndax Pharmaceuticals; UNC Lineberger Comprehensive Cancer Center
  • Class Antineoplastics; Benzamides; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Breast cancer
  • Phase II Cholangiocarcinoma; Colorectal cancer; Endometrial cancer; Follicular lymphoma; Hodgkin's disease; Leukaemia; Malignant melanoma; Neuroendocrine tumours; Non-small cell lung cancer; Pancreatic cancer; Renal cell carcinoma; Uveal melanoma
  • Phase I/II Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Phase I Solid tumours

Most Recent Events

  • 07 Aug 2018 Syndax Pharmaceuticals completes enrolment in the phase I/II ENCORE 603 trial in Fallopian tube cancer, Peritoneal cancer, Ovarian cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA
  • 07 Aug 2018 Syndax Pharmaceuticals completes enrolment in the phase I/II ENCORE 602 trial in Breast cancer (Combination therapy, Locally recurrent, Metastatic disease, Second-line therapy or greater) in USA (PO)
  • 07 Aug 2018 Syndax Pharmaceuticals in collaboration with Nektar Therapeutics plans the phase I/II ENCORE 606 trial for Malignant melanoma (Combination therapy, Second-line therapy or greater) in first half of 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top